Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation

被引：0
|
作者：
Kanda, Shintaro
Ohe, Yuichiro
Horinouchi, Hidehito
Fujiwara, Yutaka
Nokihara, Hiroshi
Yamamoto, Noboru
Sekine, Ikuo
Kunitoh, Hideo
Kubota, Kaoru
Tamura, Tomohide
机构：
[1] Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Chiba Univ, Dept Med Oncol, Chiba, Japan
[4] Mitsui Mem Hosp, Dept Resp Med, Tokyo 101, Japan
[5] Nippon Med Coll Hosp, Div Pulm Med Infect & Oncol, Dept Internal Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8064
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II STUDY OF GEFITINIB AND INSERTED CISPLATIN PLUS DOCETAXEL AS A FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION
    Ohe, Yuichiro
    Kanda, Shintaro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Kunitoh, Hideo
    Kubota, Kaoru
    Tamura, Tomohide
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S867 - S867
  • [2] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    H Asahina
    K Yamazaki
    I Kinoshita
    N Sukoh
    M Harada
    H Yokouchi
    T Ishida
    S Ogura
    T Kojima
    Y Okamoto
    Y Fujita
    H Dosaka–Akita
    H Isobe
    M Nishimura
    [J]. British Journal of Cancer, 2006, 95 : 998 - 1004
  • [3] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
  • [4] Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond
    Rocco, Danilo
    Battiloro, Ciro
    Della Gravara, Luigi
    Gridelli, Cesare
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2019, 14 (02) : 120 - 128
  • [5] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    Gridelli, C.
    De Marinis, F.
    Di Maio, M.
    Cortinovis, D.
    Cappuzzo, F.
    Mok, T.
    [J]. LUNG CANCER, 2011, 71 (03) : 249 - 257
  • [6] A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Binder, Daniel
    Hackenthal, Matthias
    Graseck, Lutz
    Schweisfurth, Hans
    Schaeper, Christoph
    Kruell, Matthias
    Temmesfeld-Wollbrueck, Bettina
    Suttorp, Norbert
    Suttorp, Thomas
    Beinert, Thomas
    Hellriegel, Klaus-Peter
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : 1144 - 1147
  • [7] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations
    Yoon, Shinkyo
    Lee, Dae Ho
    Kim, Sang-We
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (01)
  • [9] Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Kim, Young Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 692 - +
  • [10] Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study
    Tartarone, A
    Romano, G
    Iodice, G
    Capobianco, A
    Coccaro, M
    Bochicchio, A
    Di Leo, P
    Ardito, R
    Di Renzo, N
    [J]. TUMORI, 2005, 91 (02) : 131 - 134
12345